The maker of gene sequencing systems earned 87 cents a share in Q4, a 93% rise from last year that topped views by 9 cents. Revenue grew 32% to $512 mil, above estimates for $506 mil. Illumina (ILMN) says that its new HiSeq and NextSeq instruments "further enhance the most extensive sequencing portfolio available." Illumina expects '15 revenue growth of 20% and adjusted EPS of $3.12-$3.18. Analysts see 22% sales growth and EPS of $3.20. Shares rose 1.9% to 207 in after-hours trade.